Ad
related to: experimental drugs for lung cancer- About Advanced NSCLC
Find Important Info About Advanced
Non Small Cell Lung Cancer.
- Patient Support Program
Sign Up For A Patient Support
Program For This aNSCLC Treatment.
- Learn About Treatment
Discover Why This aNSCLC Treatment
Option May Be Right For You.
- aNSCLC Patient Support
Find Helpful Resources & Get
Answers About A Treatment Option.
- About Advanced NSCLC
Search results
Results from the WOW.Com Content Network
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
Experimental cancer treatments are normally available only to people who participate in formal research programs, which are called clinical trials. Occasionally, a seriously ill person may be able to access an experimental drug through an expanded access program. Some of the treatments have regulatory approval for treating other conditions.
Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen's tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday.
Glesatinib (MGCD265) is an experimental anti-cancer drug. [1] [2] It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC). [3] It is a spectrum selective tyrosine [1] kinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET". [4]
has reported phase II clinical trial results on lung cancer. [27] Tepotinib was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) in September 2019. [ 28 ] It was granted orphan drug designation in Japan in November 2019, and in Australia in September 2020.
Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. [1] [2] It was originally developed by Stemcentrx and was purchased by AbbVie. [3] It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial. [4] [5]
Ad
related to: experimental drugs for lung cancer